PSA stands for prostate-specific antigen, a protein produced by both normal and cancerous cells in the prostate gland. A simple blood test measures PSA levels, and doctors use it primarily as a screening tool for prostate cancer and to monitor prostate health. A normal PSA level is generally considered to be below 4.0 nanograms per milliliter (ng/mL), though what counts as “normal” shifts with age and other factors.
What PSA Actually Measures
The prostate gland, which sits just below the bladder in men, naturally produces PSA to help liquefy semen. Small amounts of this protein leak into the bloodstream, and that’s what the blood test picks up. The key point is that PSA is prostate-specific, not cancer-specific. Elevated levels can signal cancer, but they can also result from completely benign conditions.
PSA circulates in two forms: bound to other proteins or floating freely. The ratio between free and total PSA sometimes helps doctors distinguish between cancer and non-cancerous causes of elevated PSA. Men with prostate cancer tend to have a lower percentage of free PSA compared to total PSA.
What Raises PSA Levels Besides Cancer
Several common, non-cancerous conditions can push PSA numbers up, which is why an elevated result doesn’t automatically mean cancer:
- Benign prostatic hyperplasia (BPH): An enlarged prostate is extremely common in men over 50 and produces more PSA simply because there’s more prostate tissue.
- Prostatitis: Inflammation or infection of the prostate can cause temporary PSA spikes, sometimes dramatic ones.
- Age: PSA levels naturally rise as men get older. A reading of 2.5 ng/mL might be unremarkable at 70 but worth watching at 45.
- Recent activity: Ejaculation, vigorous cycling, and even a digital rectal exam can temporarily elevate PSA. Doctors often recommend avoiding ejaculation for 24 to 48 hours before the test.
On the flip side, certain medications can artificially lower PSA. Drugs prescribed for enlarged prostate or hair loss (5-alpha reductase inhibitors) can cut PSA levels roughly in half, which means doctors need to double the measured value to get an accurate reading in men taking those medications.
PSA Levels and What They Suggest
There’s no single cutoff that cleanly separates cancer from no cancer, but general guidelines give doctors a starting framework. A PSA below 4.0 ng/mL has traditionally been considered normal, while levels between 4.0 and 10.0 ng/mL fall into a gray zone where about 25% of men will have prostate cancer found on biopsy. Above 10.0 ng/mL, the probability of cancer rises to roughly 50%.
However, these thresholds are imperfect. Some men with PSA below 4.0 do have prostate cancer, and many men with PSA above 4.0 don’t. That’s why doctors increasingly focus on trends over time rather than any single number. A PSA that jumps from 1.5 to 3.8 in a year is more concerning than a PSA that has been sitting at 4.2 for several years. This rate of change is called PSA velocity.
Age-adjusted ranges offer another layer of interpretation. Many urologists consider these approximate upper limits of normal: 2.5 ng/mL for men in their 40s, 3.5 for men in their 50s, 4.5 for men in their 60s, and 6.5 for men in their 70s.
PSA Screening: The Debate
PSA screening has been one of the more contentious topics in preventive medicine. The core tension is straightforward: the test catches some aggressive cancers early enough to save lives, but it also detects many slow-growing cancers that would never cause symptoms or death. Treating those slow-growing cancers can lead to side effects like urinary incontinence and erectile dysfunction, meaning some men are harmed by treatment they never needed.
Large studies have shown mixed results. European research following over 160,000 men found that PSA screening reduced prostate cancer deaths by about 20%, but it also meant that for every death prevented, more than 1,000 men needed to be screened and dozens needed to be treated. An American trial initially found no mortality benefit at all, though later analyses suggested contamination between the study groups may have obscured a real effect.
Current guidelines from the U.S. Preventive Services Task Force recommend that men aged 55 to 69 make an individual decision about screening after discussing the potential benefits and harms with their doctor. For men 70 and older, routine screening is generally not recommended. Men at higher risk, including Black men and those with a family history of prostate cancer, may benefit from starting the conversation about screening earlier, in their 40s.
What Happens After an Elevated Result
An elevated PSA reading is the beginning of a diagnostic process, not a diagnosis itself. The first step is often simply repeating the test, since temporary spikes from infection, activity, or lab variability are common. If the level remains elevated, doctors typically proceed with additional evaluation.
A newer option that has become widely available is a prostate MRI, which can identify suspicious areas in the gland before any tissue is removed. MRI-targeted biopsies are more accurate than traditional random biopsies and reduce the chance of detecting insignificant cancers that don’t need treatment. If an MRI shows nothing suspicious, some men can safely avoid biopsy altogether and continue monitoring with periodic PSA tests.
When biopsy is recommended, the procedure involves collecting small tissue samples from the prostate, usually guided by ultrasound or MRI. Results come back with a Gleason score (now often reported as a Grade Group from 1 to 5) that indicates how aggressive any detected cancer appears. Grade Group 1 cancers are the slowest growing, and many men with this result are offered active surveillance, meaning regular monitoring without immediate treatment, rather than surgery or radiation.
PSA After a Cancer Diagnosis
Beyond screening, PSA becomes an invaluable monitoring tool for men already diagnosed with prostate cancer. After surgery to remove the prostate, PSA should drop to an undetectable level since the organ producing it is gone. Any measurable PSA after surgery suggests remaining cancer cells. After radiation therapy, PSA typically drops slowly over months or years, and a rising trend after reaching its lowest point may indicate the cancer has returned.
For men on active surveillance for low-grade cancer, regular PSA tests (usually every 6 to 12 months) help track whether the disease is staying stable or beginning to progress. A significant or sustained rise in PSA during surveillance is one of the triggers that may prompt a repeat biopsy or a shift toward treatment.
Other PSA-Related Tests
Because standard PSA testing produces a high rate of false positives, several refined tests have been developed to improve accuracy. The PSA density calculation divides the PSA level by the volume of the prostate (measured on ultrasound or MRI), which helps account for the fact that larger prostates naturally produce more PSA. A high PSA density is more suspicious for cancer than a high PSA in a very large gland.
Blood and urine tests that measure additional biomarkers can also help clarify borderline PSA results. These tests estimate the probability of clinically significant cancer and can help men and their doctors decide whether a biopsy is warranted. They’re particularly useful in the gray zone between 4.0 and 10.0 ng/mL, where the standard PSA test alone leaves the most uncertainty.